$PDSB News

PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors

PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer - Slideshow

PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology Corporation (PDSB) Discusses PDS-0301 Immunocytokine and Its Role in Treating Metastatic Colorectal Cancer Transcript

PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?

PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology

PDS Biotechnology Announces Publication Of Results From Phase 2 Trial Evaluating PDS0101, HPV16-Targeted Immunotherapy, In Combination With Pembrolizumab In JAMA Oncology, Peer Reviewed Journal Of American Medical Association

PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny

PDS Biotech Stock Surges Tuesday: What's Driving the Action?

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $5

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target

PDS Biotechnology Intends To Cut Workforce By 36%; Removes Stephan Toutain As COO, Effective Aug. 21

PDS Biotechnology Says Lars Boesgaard To Resign As CFO, Principal Financial Officer & Principal Accounting Officer Effective Sept 12; Frank Bedu-Addo Appointed As Interim Principal Financial Officer

PDS Biotech Reports Second Quarter 2026 Financial Results

HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Lowers Price Target to $7

PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate

PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program

PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101